about
Interaction of connexin43 and protein kinase C-delta during FGF2 signalingAngiomyogenesis for myocardial repair.Cardiomyocyte FGF signaling is required for Cx43 phosphorylation and cardiac gap junction maintenance.High molecular weight fibroblast growth factor-2 in the human heart is a potential target for prevention of cardiac remodelingIntramyocardial fibroblast myocyte communication.The Fibroblast Growth Factor signaling pathwayThe cardiokine story unfolds: ischemic stress-induced protein secretion in the heartFibroblast growth factor 2 is an essential cardioprotective factor in a closed-chest model of cardiac ischemia-reperfusion injuryGelatin Hydrogel Enhances the Engraftment of Transplanted Cardiomyocytes and Angiogenesis to Ameliorate Cardiac Function after Myocardial InfarctionLTBP-2 Has a Single High-Affinity Binding Site for FGF-2 and Blocks FGF-2-Induced Cell Proliferation.Age-related changes in rat myocardium involve altered capacities of glycosaminoglycans to potentiate growth factor functions and heparan sulfate-altered sulfationEndothelial fibroblast growth factor receptor signaling is required for vascular remodeling following cardiac ischemia-reperfusion injuryTowards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver.Cardiac-Secreted Factors as Peripheral Metabolic Regulators and Potential Disease Biomarkers.Gene targeted ablation of high molecular weight fibroblast growth factor-2.Fibroblast growth factor regulation of neovascularization.Degradable PLGA scaffolds with basic fibroblast growth factor: experimental studies in myocardial revascularizationBiological functions of the low and high molecular weight protein isoforms of fibroblast growth factor-2 in cardiovascular development and disease.Cardioprotective growth factors.Hibernating myocardium: pathophysiology, diagnosis, and treatment.The cardiogenic niche as a fundamental building block of engineered myocardium.Building and repairing the heart: what can we learn from embryonic development?A nuclear odyssey: fibroblast growth factor-2 (FGF-2) as a regulator of nuclear homeostasis in the nervous system.Trans-system mechanisms against ischemic myocardial injury.Alignment of inducible vascular progenitor cells on a micro-bundle scaffold improves cardiac repair following myocardial infarction.Cardiac actions of fibroblast growth factor 23.Delivery of growth factor-based therapeutics in vascular diseases: Challenges and strategies.Myocardial induction of nucleostemin in response to postnatal growth and pathological challenge.Immunolocalization of FGF-2 and VEGF in rat periodontal ligament during experimental tooth movement.FGF-2 and FGF-16 protect isolated perfused mouse hearts from acute doxorubicin-induced contractile dysfunction.Protection by endogenous FGF-2 against isoproterenol-induced cardiac dysfunction is attenuated by cyclosporine A.Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state.Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway.Effects of VEGF and FGF2 on the revascularization of severed human dental pulps.Cardioprotective Effects of QiShenYiQi Dripping Pills on Transverse Aortic Constriction-Induced Heart Failure in Mice.FGF-2 protects cardiomyocytes from doxorubicin damage via protein kinase C-dependent effects on efflux transporters.Induction of angiogenesis via topical delivery of basic-fibroblast growth factor from polyvinyl alcohol-dextran blend hydrogel in an ovine model of acute myocardial infarction
P2860
Q28506823-B3D8B101-4766-4975-9B34-F1F9FCE11695Q30480151-3FA9B83E-8806-4D06-90C8-3B6D1AEFDFF1Q30546913-1E38CB21-D2E4-4561-B062-62A4CFA4C32AQ31161236-422BDE68-9492-4255-95C6-32DFDF31D428Q33586605-56CB0555-EAE2-4D71-B35B-4AB35A8D8CA6Q34467171-83C1E81F-FFD8-4F42-956D-0E2078DBD434Q34809985-B253BAAF-09CE-4D36-9C29-333A13E23E26Q35294164-72A20DFF-5C14-40F5-8CDB-57B0B235C127Q35694608-BFA65285-E3C5-4B43-97D6-6BF0EBFD83DFQ35742847-7CE4A848-21F7-4949-8E25-B62FE4641B29Q35879491-74BB09C6-1AD0-437B-AA50-97BD939F918BQ36699574-4CF42376-665A-4F85-B45A-509CD3FE99A5Q36915712-F68AE200-6CA6-4CA3-B015-504D0880023DQ37076096-62903D25-3BE5-4473-8500-6E67E6A197E8Q37113792-362780C4-D22D-44A3-9359-DAF818EF5E32Q37129668-7A4B2DA3-0FD0-4249-B598-BAF69F7D61DEQ37177994-59F4B060-B9FE-428F-B1CE-EDC050DF18BBQ37261502-2F3C3B58-86E2-4B7A-97D0-A935A2F99C30Q37393585-86EDF68D-EFCB-4868-A3AD-156DB58D9DA5Q37445512-7E007E19-B638-4D7F-A068-14F9D06B82CFQ37945458-E026669F-B888-43EE-B25C-458B6291ABD5Q38215191-AC5461B7-4208-439D-826C-13F61849F5DFQ38304823-50B67AA7-7D4E-464B-A1B8-C48D69E2C2B4Q38318626-C0B12BE0-33C8-4D13-8E2E-B7ED385C9A87Q38766012-BF8EA1ED-8A5D-4E8E-A922-C95D58B09560Q38977291-68C26E7E-ECAA-4FFC-BC0C-11EB552B30ADQ39179993-E17A25B3-B985-4EAD-978D-3BE961115D07Q39976153-AD4DAF9C-4CA9-45EE-B4A6-595231AB5D63Q41837338-CD39D4E9-047D-4D65-9350-B780BA01E31AQ43707999-441EEB7F-5104-449A-8C9E-210506D60B94Q43903293-0E6DD76A-8ED6-479E-B3CE-DBB56B5856CBQ46021204-E6AB69EF-74BD-4994-8E0A-DF1F01BCFD90Q46039967-EBE7129D-CD20-461D-A116-F97D648924F9Q47219391-58C5D222-9A22-49EC-9DD5-32A2EF159F14Q52691424-37E9436B-A815-4C68-BBBA-977B1A1F771EQ54454923-F4CC2DA6-4F91-4DF1-BD51-2048586BB426Q57183653-6F111F84-A5C9-478D-9804-862E2BB14105
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Fibroblast growth factor-2 and cardioprotection.
@en
type
label
Fibroblast growth factor-2 and cardioprotection.
@en
prefLabel
Fibroblast growth factor-2 and cardioprotection.
@en
P2093
P1476
Fibroblast growth factor-2 and cardioprotection.
@en
P2093
Elissavet Kardami
Jon-Jon Santiago
Karen Detillieux
Peter A Cattini
Sarah K Jimenez
Zhisheng Jiang
P2888
P304
P356
10.1007/S10741-007-9027-0
P577
2007-12-01T00:00:00Z